Filipīnas - angļu - FDA (Food And Drug Administration)

ambica international trading corp.; distributor: mmg-fed pharma - ceftriaxone (as sodium) - powder for injection (im/iv) - 1g

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

actavis australia pty ltd - valaciclovir hydrochloride monohydrate; valaciclovir (as hydrochloride monohydrate); valaciclovir hydrochloride -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - valaciclovir hydrochloride; valaciclovir; valaciclovir (as hydrochloride) -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - valaciclovir -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - valaciclovir -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - valaciclovir hydrochloride -

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

viatris limited - valaciclovir hydrochloride monohydrate 1222.43mg equivalent to 1000 mg valaciclovir - film coated tablet - 1000 mg - active: valaciclovir hydrochloride monohydrate 1222.43mg equivalent to 1000 mg valaciclovir excipient: magnesium stearate microcrystalline cellulose opadry white oy-58900 - vaclovir is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster – associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration. vaclovir is indicated for the treatment of herpes simplex infections of the skin and mucous membranes including initial and recurrent genital herpes in immunocompetent patients. vaclovir can prevent lesion development when taken at the first signs and symptoms of an hsv recurrence. vaclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections of the skin and mucous membranes, including genital herpes in immunocompetent and immunocompromised patients. vaclovir is indicated for the prophylaxis of cytomegalovirus (cmv) infection and disease, following organ transplantation. cmv prophylaxis with vaclovir reduces acute graft rejection (renal transplant patients), opportunistic infections and other herpes virus infections (hsv, vzv).

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

viatris limited - valaciclovir hydrochloride monohydrate 305.61mg equivalent to 250 mg valaciclovir - film coated tablet - 250 mg - active: valaciclovir hydrochloride monohydrate 305.61mg equivalent to 250 mg valaciclovir excipient: magnesium stearate microcrystalline cellulose opadry white oy-58900 - vaclovir is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster – associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration. vaclovir is indicated for the treatment of herpes simplex infections of the skin and mucous membranes including initial and recurrent genital herpes in immunocompetent patients. vaclovir can prevent lesion development when taken at the first signs and symptoms of an hsv recurrence. vaclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections of the skin and mucous membranes, including genital herpes in immunocompetent and immunocompromised patients. vaclovir is indicated for the prophylaxis of cytomegalovirus (cmv) infection and disease, following organ transplantation. cmv prophylaxis with vaclovir reduces acute graft rejection (renal transplant patients), opportunistic infections and other herpes virus infections (hsv, vzv).

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

viatris limited - valaciclovir hydrochloride monohydrate 611.22mg equivalent to 500 mg valaciclovir - film coated tablet - 500 mg - active: valaciclovir hydrochloride monohydrate 611.22mg equivalent to 500 mg valaciclovir excipient: magnesium stearate microcrystalline cellulose opadry white oy-58900 - vaclovir is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster – associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration. vaclovir is indicated for the treatment of herpes simplex infections of the skin and mucous membranes including initial and recurrent genital herpes in immunocompetent patients. vaclovir can prevent lesion development when taken at the first signs and symptoms of an hsv recurrence. vaclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections of the skin and mucous membranes, including genital herpes in immunocompetent and immunocompromised patients. vaclovir is indicated for the prophylaxis of cytomegalovirus (cmv) infection and disease, following organ transplantation. cmv prophylaxis with vaclovir reduces acute graft rejection (renal transplant patients), opportunistic infections and other herpes virus infections (hsv, vzv).